Purpose: This study was designed to investigate the change of peroxisome proliferator-activated receptor gamma (PPAR ) γ after the infection of the human coronary artery smooth muscle cells (HCSMCs) with Chlamydia pneumoniae (C. pneumoniae) and the effect of PPAR agonist on the expres γ -sion of PPAR of γ C. pneumoniae-infected HCSMCs. Materials and Methods: To determine the effect of PPARγ agonist on the proliferation of C. pneumoniae-infected HCSMCs, rosiglitazone at various concentrations was applied 1 hour before inoculation of HCSMCs. Results: The expression of PPARγ mRNA in HCSMCs increased from 3 hours after C. pneumoniae infection and reached that of noninfected HCSMCs at 24 hours (p < 0.05). The expression of PPARγ protein in HCSMCs also increased from 3 hours after C. pneumoniae and persisted until 24 hours as compared with that of noninfected HCSMCs (p < 0.05). The pretreatment of HCSMCs with rosiglitazone followed by the infection with C. pneumoniae augmented the expression of PPAR mRNA and γ protein (p < 0.05) and decreased cell proliferation. Conclusion: Our results showed that the expression of PPAR increases in γ response to C. pneumoniae infection and rosiglitazone further augmented the expression of PPAR . It is suggested that γ rosiglitazone could ameliorate the chronic inflammation in the vessel wall induced by C. pneumoniae by augmenting PPARγ expression.
INTRODUCTION
Infection has attracted attention as a novel risk factor for atherosclerosis, which is different from traditional risk factors. 1 Among various infectious agents, Chlamydia pneumoniae (C. pneumoniae) is the major infectious agent that has been extensively investigated. Seroepidemiological studies showed that the seropositivity of anti-C. pneumoniae antibodies is two times higher in patients with cardiovascular diseases than that of healthy population controls. 2 Furthermore C. pneumoniae were isolated from more than half of atherosclerotic lesions. 3 In vitro studies suggest that C. pneumoniae could be detected in circulating leukocytes, and that they infect all atheroma cell types such as endothelial cells, vascular smooth muscle cells (VSMC), and macrophages, [4] [5] [6] and induce the inflammatory cytokines, procoagulants, matrix metalloproteinases and adhesion molecules. [7] [8] [9] Peroxisome proliferator-activated receptor-γ (PPAR ) is a member of the nuclear receptor γ superfamily that regulates lipid and lipoprotein metabolism and glucose homeostasis. In addition, PPAR has been reported to be an important γ modulator of the inflammatory response of vessel wall not only through metabolic effects but also through their direct action in vascular and inflammatory cells. 10, 11 PPAR is expressed in the γ major cellular constituents of the vessel wall such as endothelial cells, VSMC, and macrophages, and affects development of atherosclerosis. 12, 13 In endothelial cells, PPAR agonist inhibits the γ expression of monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1. 14,15 PPAR also γ interferes with leukocyte chemoattraction and recruitment to atherosclerotic lesions and suppresses the expression of inducible nitric oxide synthase and matrix metalloproteinase-9 (MMP-9) in macrophages. Furthermore, PPAR inhibits γ VSMC proliferation by attenuating the mitogeninduced degradation of p27Kip1, and plateletderived growth factor-induced VSMC migration by inhibiting MMP-9 expression. 11, 16 Although a number of studies indicate the role of PPAR in the modulation of vascular inflam γ -mation, the effect of atheroprone infectious agents on the expression of PPAR in vascular cells has
γ not yet been studied. Interestingly, infection increases PPAR expression in porcine white γ blood cells 17 but down-regulates it in murine adipocytes, 18 suggesting that PPAR expression is γ differentially regulated according to cell types. We hypothesized that C. pneumoniae infection, which is a clear risk factor for the development of atherosclerosis, may have an effect on the expression of PPAR in vascular smooth muscle γ cells. Therefore, the present study was undertaken to investigate whether C. pneumoniae infection could affect the expression of PPAR in human γ coronary artery smooth muscle cells (HCSMC).
MATERIALS AND METHODS

Cell lines
Human coronary artery smooth muscle cells (HCSMC) were purchased from Clonetics and cultured in SmBm media (smooth muscle cell basal media, Clonetics, Walkersville, MD, USA). Passages between 5 and 10 were used.
C. pneumoniae
C. pneumoniae AR-39 strain was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The organisms were inoculated into shell vials containing McCoy cells (ATCC, Manassas, VA, USA), and then shell vials were centrifuged at 1500g for 1 hour and incubated in RPMI 1640 medium containing 1 g/mL μ cycloheximide (Sigma, St. Louis, MO, USA). After 48 hours, the infected cells were disrupted by ultrasonication, and culture supernatants and cell debris were removed by centrifugation at 800g for 10 minutes. The organisms were then concentrated by a high-speed centrifugation at 30,000g for 30 minutes. The bacterial pellets were resuspended in sucrose phosphate glutamate transport medium and stored at -70 until use. The organisms resuspended in RPMI 1640 medium were used for experiments. The number of infectious C. pneumoniae was determined as inclusion forming units per mL by counting chlamydial inclusions formed in McCoy cells with fluorescein isothiocyanateconjugated C. pneumoniae-specific monoclonal antibody (DAKO, Copenhagen, Denmark).
Infection of HCSMC with C. pneumoniae
HCSMCs were trypsinized and plated at a density of 4 × 10 5 cells/well on 6-well plates. Once confluent, the medium was then changed to serum-free medium for 24 hour to achieve synchronous growth arrest. HCSMCs were inoculated with C. pneumoniae at a multiplicity of infection (MOI) of 2, and the plates were centrifuged at 500g for 1 hour at room temperature. Multiple inclusion bodies in HCSMCs were observed after 48 hours of C. pneumoniae infection.
Cell proliferation assay
HCSMCs were plated at a density of 5 × 10 3 cells/well on 96-well plates and inoculated with C. pneumoniae by the method described above. Cell proliferation was determined using XTT proliferation assay kit (JBI, Deagu, Korea) 6 hours, 24 hours and 48 hours after inoculation. As a control for cell proliferation, noninfected HCSMCs were used. To determine the effect of a PPAR agonist γ on the proliferation of C. pneumoniae-infected HCSMCs, rosiglitazone (GlaxoSmithKline Corporate, King of Prussia, PA, USA) at various concentrations was applied 1 hour before inoculation.
Real time reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from HCSMCs using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Total extracted RNA was subjected to reverse transcription using an onestep RT kit (Invitrogen). Expressions of PPAR and glyceraldehyde 3-phosphate γ dehydrogenase (GAPDH) were examined in real time PCR using an SYBR Green dye. Primers used were as follows: human PPAR sense, 5'-TCTCTC γ CGTAATGGAAGACC-3', human PPAR anti γ -sense, 5'-CCCCTACAGAGTATTACG-3'; GAPDH sense, 5'-TGCACCACCAACTGCTTAGC-3', GAPDH antisense 5'-GGCATGGACTGTGGTCAT GAG-3'. To examine the changes in the expression of PPAR mRNA according to time elapse after γ C. pneumoniae infection in HCSMCs, relative values were compared at various time intervals.
Western blot analysis
HCSMCs were seeded at 4 × 10 5 cells/well in 6-well plates and incubated with C. pneumoniae. After various time intervals, cells were harvested, lysed, and sonicated in Tris-lysate buffer [20 mM Tris-HCl (pH 7.4), 5 mM EDTA, 10 mM Na2P2O7, 100 mM NaF, 2 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10 g/mL aprotinin, 10 μ g/ μ mL leupeptin]. Cell lysate were cleared by centrifugation, and protein concentrations were determined by Bradford protein assay kit (Pierce, Rockford, IL, USA). Proteins were resolved on a 9% sodium dodecylsulfate-polyacrylamide gel, and electrophorectically transferred onto a nitrocellulose membrane. The membrane was incubated with anti-PPAR monoclonal antibody (Santa γ Cruz Biotechnology, Santa Cruz, CA, USA). HRPconjugated anti-mouse IgG (Amersham Bioscience, Piscataway, NJ, USA) was used as a secondary antibody. The antigen-antibody complexes were detected using enhanced chemilumnescence kit (Amersham Bioscience). Quantification of the protein band was done by densitometry.
Statistics
Statistical analysis was performed using the Statistical Package for Social Sciences (version 10, SPSS Inc., Chicago, IL, USA). Values of continuous variables are expressed as mean ± standard deviation. Comparisons of data were made using Student t-test. P-values less than 0.05 were considered as indicative of statistical significance.
RESULTS
C. pneumoniae stimulates HCSMCs proliferation
HCSMC proliferation was compared between C. pneumoniae-infected and uninfected-HCSMCs, according to time intervals such as 6, 24, and 48 hours after infection at a MOI of 2. As shown in Fig. 1 , HCSMCs proliferation was stimulated after inoculation with C. pneumoniae in a time-dependent manner. At 48 hours, XTT assay showed that C. pneumoniae significantly increased the number of HCSMCs compared to the uninfected control (Fig. 1) .
Rosiglitazone suppresses C. pneumoniae-induced proliferation of HCSMCs.
To explore whether PPAR activation directly γ affects C. pneumoniae-induced HCSMCs proliferation, the proliferation rate was compared between C. pneumoniae-infected HCSMCs and rosiglitazonetreated C. pneumoniae-infected HCSMCs. Treatment of HCSMCs with 10 and 50 M rosiglitazone μ significantly decreased the C. pneumoniae-induced proliferation of HCSMCs from 5 hours after C. pneumoniae infection and from 8 hours even at 1 M concentration (Fig. 2) . μ
C. pneumoniae upregulates the expression of PPAR mRNA expression in HCSMCs γ
To determine whether C. pneumoniae activates PPAR mRNA in HCSMCs, cells were left γ untreated or stimulated with C. pneumoniae, and cDNA was then prepared from each HCSMCs after 3-, 6-, and 24-hour exposure to C. pneumoniae. The expression of PPAR mRNA was evaluated γ by real time RT-PCR. The levels of PPAR mRNA γ were significantly increased in HCSMCs 3 hours after C. pneumoniae inoculation, and remained elevated until 6 hours after infection as compared with uninfected control. At 24 hours, the level of PPAR mRNA in HCSMCs infected with γ C. pneumoniae returned to the level of uninfected control (Fig. 3) .
C. pneumoniae stimulates the expression of PPARγ protein in HCSMCs
To investigate whether C. pneumoniae infection affects PPAR protein expression in HCSMCs, γ cells were stimulated with C. pneumoniae infection for 3, 6, and 24 hours. Cell lysates were analyzed by Western blot using a anti-PPAR monoclonal γ antibody. The levels of PPAR protein were γ already increased in HCSMCs after 3-hour exposure to C. pneumoniae as compared with uninfected HCSMCs, and the status of elevation was maintained until 24 hours (Fig. 4) . 
pneumoniae-infected HCSMCs
The observation that C. pneumoniae has a stimulatory effect on PPAR protein in HCSMCs pro γ -mpted us to investigate the potential synergistic effect of rosiglitazone on the expression of PPARγ in HCSMCs. Thus, HCSMC cells were divided into untreated control, C. pneumoniae-inoculated, rosiglitazone (20 M)-treated, and co-treated with μ both rosiglitazone and C. pneumoniae. Changes in the expression of PPAR in each HCSMCs were γ evaluated by Western blot 24 hours after treatment. As compared with untreated control, both rosiglitazone and C. pneumoniae significantly increased the expression of PPAR protein in HCSMCs.
γ Interestingly, co-treatment of HCSMCs with rosiglitazone and C. pneumoniae resulted in an additive effect on the expression of PPAR protein (Fig. 5) .
γ
DISCUSSION
The present study shows that C. pneumoniae could upregulate the expression of PPAR mRNA γ and protein in HCSMCs, and PPAR activator γ further increased its expression in concert with C. pneumoniae. In addition, rosiglitazone significantly attenuated C. pneumoniae-induced proliferation of HCSMCs. Our results suggest that PPAR palys γ a role in the development of atherosclerosis induced by C. pneumoniae. It is suggested that rosiglitazone, a PPAR agonist, could prevent the γ development of atherosclerosis through its antiinflammatory and anti-atherogenic effects.
C. pneumoniae could infect and proliferate within endothelial cells, vascular smooth muscle cells, and macrophages, and evoke inflammatory response in these cells. [4] [5] [6] [7] [8] [9] Animal model studies have shown that C. pneumoniae could infect vessel wall and cause arterial inflammation, which leads to the initiation and development of atherosclerotic lesions. 19, 20 In contrast, PPAR has an γ important effect of inhibiting growth and migration of all vascular cells, and reducing vessel inflammation, which leads to attenuation of atherosclerosis in the vessel wall. 12 showed that the expression of PPAR was γ upregulated in the endothelial cells in mice infected with C. pneumoniae. 25 In the present study, we also observed that C. pneumoniae stimulated the expression of PPAR in vascular smooth γ muscle cells. This observation was contrary to the expectation that C. pneumoniae might suppress the expression of PPAR because of their counter γ -balancing actions on all the vascular cells and vessel walls. However, the mechanisms of C. pneumoniae-induced PPAR activation in HCSMCs γ are not clear. C. pneumoniae is a Gram-negative bacterium, and its cell wall is rich in lipopolysaccharides, which can induce hepatocytes and macrophages to secret prostaglandin (PG) D2. 26, 27 15d-PGJ2, a metabolite of PGD2, is a ligand for PPAR and can induce the PPAR expression. γ γ Further study is needed to elucidate in detail the mechanism of C. pneumoniae-induced PPARγ upregulation in vitro.
The increase of PPAR expression may act as an γ counter-regulatory mechanism of attenuating the negative effect of C. pneumoniae in HCSMCs. Rosiglitazone suppressed C. pneumoniae-induced proliferation of HCSMCs and further elevated the expression of PPAR protein. It might be a novel γ mechanism of PPAR activators to be protective γ against the atheroprone C. pneumoniae. Further studies are required to clarify the association and influence between infection and PPAR in γ vascular cells as well as in animal models.
